Skip to content
DataLookout
Menu

ROSY-SNCT07691970

Rollover Study for Participants Who Have Completed a Previous Clinical Study With Anifrolumab (Saphnelo) and Clinically Benefited From Continued Treatment

StatusRecruiting
PhasePhase 3
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 4 versions: 4 with changes below. See every version on ClinicalTrials.gov ↗

  1. Minor Trial sites expanded: 153 → 166 locations
  2. Minor Trial sites expanded: 128 → 153 locations
  3. Notable Recruitment opened Show 4 more changesShow less
    • Eligibility criteria expanded, about 15 words
    • Trial sites expanded: 41 → 128 locations
    • Primary and study completion dates: Dec 31, 2032 to Dec 30, 2032
    • Start date changed from estimate of Sep 1, 2026 to Aug 31, 2026
  4. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

SAEs and Non-Serious AEs
Timeframe: From first dose administered and until 12 weeks after the last dose of Anifrolumab

Arms and interventions

AnifrolumabExperimental

This is a single arm open-label study with the primary objective of providing continued access to anifrolumab to eligible participants who are continuing to derive clinical benefit from treatment and assessing long-term safety and tolerability of anifrolumab until participant meets one of the study discontinuation criteria.

Combination products: Anifrolumab

Drugs: Anifrolumab

Sites

166 sites in 35 countries

United States 21, Spain 14, Germany 13, France 10, Italy 10, China 8, Poland 8, Japan 6, United Kingdom 6, Brazil 5, Mexico 5, South Korea 5, Taiwan 5, Thailand 5, Austria 4, Bulgaria 4, India 4, Australia 3, Philippines 3, Portugal 3, Romania 3, Argentina 2, Belgium 2, Canada 2, Israel 2, Serbia 2, Slovakia 2, Turkey (Türkiye) 2, Chile 1, Colombia 1, Czechia 1, Greece 1, Netherlands 1, South Africa 1, Vietnam 1